Wyeth reports earnings results for 4Q and year 2005. [3 tables].

(From Chemical Business NewsBase - Company Reports - CBNB)

Wyeth reported results for 4Q and full year ended Dec 2005. Worldwide net revenue increased to $4.7 bn for 4Q 2005 and to $18.8 bn for year ended Dec 2005. Enbrel sales in North America, reported by Wyeth's marketing partner Amgen, were $674 M for 4Q 2005 and $2.6 bn for 2005. Wyeth has exclusive rights to Enbrel outside of North America where net revenue was $298 M for 4Q 2005 and $1.1 bn for 2005. Enbrel is a breakthrough product approved for the treatment of chronic inflammatory diseases. Worldwide sales surpassed $3.6 bn for 2005. Worldwide net revenue for Effexor (Effexor and Effexor XR), the number one …